[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585994":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":30,"responsibleParty":47,"collaborators":49,"id":54,"slug":19,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":19,"enrollmentInfo":63,"targetDuration":19,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":32,"whyStopped":19,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"HER2 expression of PET imaging","EXPERIMENTAL","Evaluate the predict potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in breast cancer patients treated with ADC therapy",[13],"Radiation: HER2 expression of PET imaging",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"RADIATION","Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in breast patients treated with ADC therapy",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Xiaoyi Guo, PhD","CONTACT","010-88196495","15833916752@163.com",{"name":27,"role":23,"phone":28,"phoneExt":19,"email":29},"Yannan Yuan","01088197730","gcp_yuanyn@bjcancer.org",[31],{"facility":5,"status":32,"city":33,"state":19,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Beijing","100142","China","CN",{"type":38,"coordinates":39},"Point",[40,41],116.39723,39.9075,{"lat":41,"lon":40},[44,46],{"name":22,"role":23,"phone":45,"phoneExt":19,"email":25},"01088196495",{"name":27,"role":23,"phone":28,"phoneExt":19,"email":29},{"type":48,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[50,52],{"name":51,"class":6},"The Affiliated Hospital of Qingdao University",{"name":53,"class":6},"North Sichuan Medical College","100585994",false,"NCT06909604","Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy","Al18F-HER2-BCH PET\u002FCT to Predict Response in Breast Patients Treated With ADC Therapy","FHERAD","Inclusion Criteria:\n\n1. Aged ≥18 years old; ECOG 0 or 1;\n2. Patients with HER2 positive or low tumors;\n3. Receives neoadjuvant therapy\n4. Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions;\n5. Life expectancy \\> 3 months -\n\nExclusion Criteria:\n\n1. Significant hepatic or renal dysfunction;\n2. Is pregnant or ready to pregnant;\n3. Cannot keep their states for half an hour;\n4. Refused to join the clinical research;\n5. Suffering from claustrophobia or other mental disorders;\n6. Any other situation that researchers considered it unsuitable to participate in the trial.","ALL","18 Years",{"count":64,"type":65},50,"ESTIMATED","INTERVENTIONAL",[68],"NA","To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with ADC therapy",[71],"Breast Cancer",[73,74,75,76],"breast cancer","PET\u002FCT","HER2 expression","ADC therapy","2026-05-08",{"date":79,"type":80},"2026-05-13","ACTUAL",{"date":82,"type":80},"2025-01-01",{"date":84,"type":65},"2026-12-30",{"name":5,"class":6},1]